Director/PDMR Shareholding
28 Octobre 2008 - 7:24PM
UK Regulatory
RNS Number : 8912G
Protherics PLC
28 October 2008
Protherics PLC
Notification of Directors' Interests
London, UK; Brentwood, TN, US: 28 October 2008 - Protherics PLC ("Protherics" or the "Company"), the international biopharmaceutical
company focused on critical care and cancer, in accordance with the FSA Disclosure and Transparency Rules, announces that, on 23 October
2008, pursuant to the conversion of all outstanding six per cent. unsecured convertible loan notes 2010 of Protherics, the following
ordinary shares (the "Shares") were allotted to Directors of Protherics PLC:
Director Nominal Value of Loan Shares allotted share capital % issued
Notes converted
Andrew Heath �24,242 96,968 0.028%
Stuart Wallis �60,606 242,424 0.069%
In accordance with the Loan Note Instrument, the Shares were allotted at a price of 25 pence per share.
Following the above allotment of Shares, their interests in the ordinary share capital of the Company are as follows:
No. Shares % issued share capital
Andrew Heath 516,778 0.148%
Stuart Wallis 809,113 0.231%
| Ends |
For further information please contact:
Protherics
Nick Staples, Director of Corporate Affairs +44 (0) 7919 480510
Julie Vickers, Company Secretary +44 (0)1928 518010
Financial Dynamics - press enquiries
London: Ben Atwell, Lara Mott +44 (0) 20 7831 3113
New York: John Capodanno +1 212 850 5600
Or visit www.protherics.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
RDSMPBPTMMTTBJP
Protherics (LSE:PTI)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
Protherics (LSE:PTI)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024
Real-Time news about Protherics (London Stock Exchange): 0 recent articles
Plus d'articles sur Protherics Plc